Multiplex immunoassay for quantification of antigens of diphtheria, tetanus and acellular pertussis in human combined DTaP vaccines
Scope of the method
- Human health
- Basic Research
- In vitro - Ex vivo
- Animal derived cells / tissues / organs
- quality control
The multiplex immunoassay is based on the Luminex technology and allows the detection of diphtheria, tetanus and acellular pertussis antigens of human combined vaccines in the same run. As potency test of these vaccines are currently performed on animal through challenge and/or serological assays, the use of such in-vitro method for the quality control of DTaP vaccines would significantly reduce the number of used animals.
- - Luminex Magpix;
- - Luminex 200 or equivalent;
- - Incubator 37°C;
- - Fridge;
- - Centrifuge;
- - Ultrasonic bath.
- Still in development
Pros, cons & Future potential
- - Allows quantification of several antigens in one run;
- - Reduce/abolish the number of animals used for the quality control of vaccines.
Reading time (+/-45min) for one plate compared to an ELISA plate (instantaneous).
The method was developed on adsorbed antigens and final vaccine formulation but a desorption step could be required for some vaccines.
Development was performed on vaccines from two manufacturers but could be expanded for the use on vaccines from other manufacturers.
References, associated documents and other information
Contact personMaxime Vermeulen
Quality of vaccines and blood products